Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
BPC-157 Vial is strictly intended for use by
These results established tirzepatide as the most potent agent in the current pharmacologic armamentarium for obesity
Potential Side Effects and Safety Considerations Whilst combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors is generally well-tolerated, patients and healthcare professionals must be aware of potential adverse effects associated with each drug class
As of 2026, BPC-157 is not approved by Health Canada for human or veterinary use and remains restricted to research-use-only contexts
For a complete cost breakdown, see our cheapest tirzepatide options
Acosta-Rodrguez, V
US$ 27.00
US$ 27.61
US$ 21.89
